ArticleOncoTargets and therapy2010
Update on options for treatment of metastatic castration-resistant prostate cancer.
Article in OncoTargets and therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.Cancer immunology, immunotherapy : CII · 2013Trial
- Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.British journal of cancer · 2012Trial
- Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men.Cancer chemotherapy and pharmacology · 2012Trial
- Vaccine Therapies for Cancer: Then and Now.Targeted oncology · 2021Review
- Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy.Journal of experimental & clinical cancer research : CR · 2016Article
- Active Holistic Surveillance: The Nutritional Aspect of Delayed Intervention in Prostate Cancer.Journal of nutrition and metabolism · 2016Article
- Sensitization to docetaxel in prostate cancer cells by green tea and quercetin.The Journal of nutritional biochemistry · 2015Article
- NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Activation of Wnt/β-catenin signaling in a subpopulation of murine prostate luminal epithelial cells induces high grade prostate intraepithelial neoplasia.The Prostate · 2014Article
- Prostate cancer vaccines in combination with additional treatment modalities.Immunologic research · 2014Review
- NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.PloS one · 2014Article
- Complete regression of advanced prostate cancer for ten years: A case report and review of the literature.Oncology letters · 2013Article
- Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?Prostate cancer and prostatic diseases · 2013Review
- [Second line therapy for castration-resistant prostate cancer (CRPC)].Der Urologe. Ausg. A · 2012Review
- The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.Cancer management and research · 2012Article
- Castration-resistant prostate cancer: mechanisms, targets, and treatment.Prostate cancer · 2012Article
- CXCR4 expression in prostate cancer progenitor cells.PloS one · 2012Article
- Fibroblast growth factor and ornithine decarboxylase 5'UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN(-/-) transgenic mice.Cancer gene therapy · 2012Article
- Prolonged remission of fulminant castrate-resistant prostate cancer: a case report.Clinical genitourinary cancer · 2011Article
- Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.Journal of hematology & oncology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is one of the most common cancers in men in US and European countries. Despite having a favorable prognosis, the incidence of incurable metastatic disease and mortality in the US is about 28,000 per year. Although hormone-based androgen deprivation therapies typically result in rapid responses, nearly all patients eventually develop progressive castration-resistant disease state. With readily available prostate-specific antigen (PSA) testing, most of these patients are asymptomatic and manifest progression simply as a rising PSA. In patients with castration-resistant prostate cancer (CRPC), the median survival is about 1-2 years, with improvements in survival seen mostly with docetaxel-based regimens. The purpose of this article is to review the recent developments in the treatment of advanced CRPC. RECENT
findingsSince the two landmark trials (TAX-327 and Southwest Oncology Group 99-16) in CRPC, several newer cytotoxic drugs (epothilones, satraplatin), targeted agents (abiraterone, MDV3100) and vaccines have been tested in phase II and III setting with promising results.
conclusionsThe role of newer agents in the treatment of CRPC still needs to be validated by phase III trials, which are currently ongoing. Whilst the novel biomarkers, 'circulating tumor cells', have been shown to provide important prognostic information and are anticipated to be incorporated in future clinical decision-making, their exact utility and relevance calls for a larger prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.